Former Aetna CEO suggests separating special enrollment customers on exchanges

A separate risk pool for customers who purchase insurance from the Affordable Care Act (ACA) exchanges during the special enrollment period could help stabilize the market, argued former Aetna CEO and chairman Ronald Williams.

Williams, writing in an op-ed published by the Wall Street Journal, said while CMS has made adjustments to the marketplace, insurers could be lured back in by changes which prevent customers from buying coverage when they need health care services, then cancelling it once they don’t.

“We could place consumers enrolling during the Special Enrollment Period (SEP) into special risk pools separate from the federal health exchanges,” Williams wrote. “These risk pools could be made available for this specific purpose, and be monitored and managed by insurers. Risk pools existed in many states prior to the [ACA] and some states are considering reinstating them. Another option would be refundable tax credits, which are similar to paying for health insurance through taxes.”

If special enrollment periods will remain, Williams said health agencies should require customers to prove they’re eligible—the same standard included in a proposed rule from HHS released in June.

For more on Williams’ thoughts on ways to attract insurers back to the exchanges, click on the link below: 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.